Aequus Pharmaceuticals Inc (AQS) - Total Liabilities

Latest as of September 2025: CA$7.09 Million CAD ≈ $5.13 Million USD

Based on the latest financial reports, Aequus Pharmaceuticals Inc (AQS) has total liabilities worth CA$7.09 Million CAD (≈ $5.13 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Aequus Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.

Aequus Pharmaceuticals Inc - Total Liabilities Trend (2013–2024)

This chart illustrates how Aequus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Aequus Pharmaceuticals Inc total assets.

Aequus Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Aequus Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Faron Pharmaceuticals Oy LSE:FARN	UK	GBX32.45 Million
Watkin Jones PLC LSE:WJG	UK	GBX165.03 Million
Craven House Capital PLC LSE:CRV	UK	$1.93 Million
STMicroelectronics NV LSE:0INB	UK	€7.83 Billion
Angling Direct PLC LSE:ANG	UK	GBX27.71 Million
Zapp Electric Vehicles Group Limited Ordinary Shares NASDAQ:ZAPP	USA	$27.91 Million
PURANIUM ENERGY LTD. F:2DK	Germany	€304.99K
Baosheng Media Group Holdings Ltd NASDAQ:BAOS	USA	$9.13 Million

Liability Composition Analysis (2013–2024)

This chart breaks down Aequus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Aequus Pharmaceuticals Inc balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.03	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.03	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	36.14	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aequus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aequus Pharmaceuticals Inc (2013–2024)

The table below shows the annual total liabilities of Aequus Pharmaceuticals Inc from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	CA$7.26 Million ≈ $5.25 Million	+34.85%
2023-12-31	CA$5.38 Million ≈ $3.89 Million	+75.16%
2022-12-31	CA$3.07 Million ≈ $2.22 Million	+20.03%
2021-12-31	CA$2.56 Million ≈ $1.85 Million	-0.07%
2020-12-31	CA$2.56 Million ≈ $1.85 Million	+0.43%
2019-12-31	CA$2.55 Million ≈ $1.84 Million	+709.71%
2018-12-31	CA$314.90K ≈ $227.79K	-14.16%
2017-12-31	CA$366.84K ≈ $265.36K	-50.72%
2016-12-31	CA$744.41K ≈ $538.50K	-34.99%
2015-12-31	CA$1.15 Million ≈ $828.33K	+53.80%
2014-12-31	CA$744.51K ≈ $538.56K	+1212.23%
2013-12-31	CA$56.74K ≈ $41.04K	--

About Aequus Pharmaceuticals Inc

V:AQS Canada Drug Manufacturers - Specialty & Generic

Market Cap

$479.73K

CA$663.17K CAD

Market Cap Rank

#31080 Global

#1647 in Canada

Share Price

CA$0.01

Change (1 day)

+0.00%

52-Week Range

CA$0.01 - CA$0.01

All Time High

CA$0.69